ALECR Stock Overview
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Eurofins-Cerep SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €23,000.00 |
52 Week High | €29,200.00 |
52 Week Low | €22,200.00 |
Beta | 0.58 |
1 Month Change | 0% |
3 Month Change | -8.00% |
1 Year Change | n/a |
3 Year Change | 64.29% |
5 Year Change | 245.86% |
Change since IPO | 391.98% |
Recent News & Updates
Shareholder Returns
ALECR | FR Life Sciences | FR Market | |
---|---|---|---|
7D | 0% | 3.6% | -0.4% |
1Y | n/a | -3.8% | 10.6% |
Return vs Industry: Insufficient data to determine how ALECR performed against the French Life Sciences industry.
Return vs Market: Insufficient data to determine how ALECR performed against the French Market.
Price Volatility
ALECR volatility | |
---|---|
ALECR Average Weekly Movement | 2.2% |
Life Sciences Industry Average Movement | 6.2% |
Market Average Movement | 4.3% |
10% most volatile stocks in FR Market | 10.0% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALECR has not had significant price volatility in the past 3 months.
Volatility Over Time: ALECR's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 209 | Antoine Duthilleul | https://www.eurofins.fr/cerep/ |
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company’s research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014.
Eurofins-Cerep SA Fundamentals Summary
ALECR fundamental statistics | |
---|---|
Market cap | €116.01m |
Earnings (TTM) | €11.52m |
Revenue (TTM) | €47.65m |
10.1x
P/E Ratio2.4x
P/S RatioIs ALECR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALECR income statement (TTM) | |
---|---|
Revenue | €47.65m |
Cost of Revenue | €24.01m |
Gross Profit | €23.64m |
Other Expenses | €12.11m |
Earnings | €11.52m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 2.28k |
Gross Margin | 49.61% |
Net Profit Margin | 24.19% |
Debt/Equity Ratio | 0.009% |
How did ALECR perform over the long term?
See historical performance and comparison